Insider trades

Samuel Kintz, CEO of Enliven Therapeutics ELVN, has filed 0 purchases and 52 sales on the open market. Over the past 12 months that comes to a net sale of $539.4K. The latest trade was on 25/11/17.

Samuel Kintz

President and CEO
First filing
23/02/27
Trades
84 trades
Buys / sales
0 / 52
12-month net buying
−$539.4K
Last trade
25/11/17

Trading activity

Transactions

Trade type
Open-market sale10b5-1 plan25/11/1725/11/1912,500 sh$21.82$272,750−1.4%
Open-market sale10b5-1 plan25/10/1725/10/2112,500 sh$21.33$266,625−1.4%
Open-market sale10b5-1 plan25/09/2625/09/303,700 sh$20.06$74,222−0.4%
Open-market sale10b5-1 plan25/09/2325/09/252,800 sh$20.03$56,084−0.3%
ELVN
Open-market sale10b5-1 plan25/09/17–25/09/1925/09/196,000 sh2 trades$19.28avg.$115,700−0.6%
Open-market sale10b5-1 plan · Amendment25/08/2025/08/211,517 sh$20.00$30,340−0.2%
ELVN
Open-market sale10b5-1 plan25/08/18–25/08/1925/08/2010,983 sh2 trades$20.02avg.$219,867.86−1.2%
ELVN
Open-market sale10b5-1 plan25/07/1725/07/2112,500 sh3 trades$22.52avg.$281,509.34−1.3%
ELVN
Open-market sale10b5-1 plan25/06/1725/06/1812,500 sh2 trades$22.19avg.$277,338.66−1.3%
Open-market sale10b5-1 plan25/06/0325/06/057,500 sh$20.05$150,375−0.8%
Open-market sale10b5-1 plan25/05/1925/05/215,000 sh$16.49$82,450−0.5%
ELVN
Open-market sale10b5-1 plan25/05/01–25/05/0225/05/057,500 sh2 trades$20.06avg.$150,426.4−0.8%
Open-market sale10b5-1 plan25/04/1725/04/215,000 sh$16.42$82,100−0.5%
Open-market sale10b5-1 plan25/03/1725/03/1912,500 sh$20.83$260,375−1.2%
Open-market sale10b5-1 plan24/10/1824/10/22924 sh$30.00$27,720−0.1%
ELVN
Open-market sale10b5-1 plan24/10/08–24/10/0924/10/1029,977 sh4 trades$28.06avg.$841,220.15−2.9%
ELVN
Open-market sale10b5-1 plan24/10/04–24/10/0724/10/0814,936 sh2 trades$27.51avg.$410,862.06−1.4%
Open-market sale10b5-1 plan24/10/0124/10/03526 sh$27.54$14,486.04−0.1%
Open-market sale10b5-1 plan24/08/2624/08/2812,000 sh$22.89$274,680−1.1%
Open-market sale10b5-1 plan24/07/3124/08/022,270 sh$27.56$62,561.2−0.2%